Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 6/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.43 |
| ▸ | DRD2 | P14416 | 8/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25031448 | 1.00 | DDB1 (0.43) | DDB1CRBNDRD2DRD3F10 | |
| SCHEMBL25941035 | 0.94 | CRBN (0.43) | DDB1CRBNDRD2DRD3F10 | |
| SCHEMBL30981249 | 0.94 | CRBN (0.43) | DDB1CRBNDRD2DRD3F10 | |
| SCHEMBL30965823 | 0.92 | CRBN (0.44) | DDB1CRBNDRD2DRD3PIM1 | |
| SCHEMBL30135779 | 0.88 | CRBN (0.41) | DDB1CRBN | |
| SCHEMBL27039703 | 0.88 | CRBN (0.42) | DDB1CRBNDRD2DRD3PIM1 | |
| SCHEMBL31653870 | 0.88 | DDB1 (0.52) | DDB1CRBNF10PIM1PIM3 | |
| SCHEMBL30135798 | 0.88 | ALDH1A1 (0.38) | DDB1CRBN | |
| SCHEMBL25822081 | 0.88 | DDB1 (0.45) | DDB1CRBNDRD2DRD3F10 | |
| SCHEMBL25262031 | 0.87 | CRBN (0.37) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | DDB1 132/4885CRBN 2136/4885DRD2 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.